BioSpace News Archive

As its acquisition by Takeda Pharmaceutical edges closer and closer, Shire reported a solid second-quarter.

Getting noticed in your workplace sometimes requires more than simply completing your tasks or meeting your goals. In order to be a true stand-out at work and position yourself as an integral player in your organization, the unique value that you bring on a daily basis needs to be communicated in a variety of ways over time, some professional and some personal.

Do you find it difficult to make time to go to the gym or keep up with a regular exercise program outside of work? If your work schedule doesn’t permit spending hours at the gym or exercising every week, you should do your best to find creative ways to incorporate physical activity into your workday.

The U.S. Food and Drug Administration (FDA) approved New York-based Progenics Pharmaceuticals’ New Drug Application (NDA) for Azedra for adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. It is the first and only therapy approved for these indications.

Active Biotech, based in Lund, Sweden, announced that its laquinimod failed to meet its primary endpoint in its Phase II clinical trial for Huntington’s disease.

Deal Broadens Hologic’s Breast Health Product Portfolio and Expands Company’s Role in Breast Health Care

INGREZZA® (valbenazine) Second Quarter Net Product Sales of $96.9 Million with Approximately 16,700 TRx

Company Tops Revenue and EPS Guidance

Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT

An issue covering major clinical findings and managed care updates from the annual meeting of the American Society of Clinical Oncology is now available from Evidence-Based Oncology™, a publication of The American Journal of Managed Care®.